Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 18, 2022
SEOM-TTCC clinical guideline in nasopharynx cancer (2021)Antonio Rueda Domínguez, Beatriz Cirauqui, Almudena García Castaño, et al.
Frontiers in Immunology|September 29, 2025
Low rather than high interleukin-6 levels are associated with immune-related adverse events in cancer patients treated with immune checkpoint inhibitorsIñigo Les, David de Haedo, Mireia Martínez, et al.
Head & Neck|October 4, 2023
Circulating low density neutrophils are associated with resistance to anti-PD1 immunotherapy in squamous head and neck cancerVirginia Arrazubi, Saioa Goñi, Iranzu González-Borja, et al.
Cancers|July 28, 2019
Omics Approaches in Pancreatic AdenocarcinomaIranzu González-Borja, Antonio Viúdez, Saioa Goñi, et al.
Scientific Reports|July 13, 2024
Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinomaIbone Labiano, Ana E Huerta, Maria Alsina, et al.
Cancers|December 11, 2022
Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic AdenocarcinomaIranzu González-Borja, Antonio Viúdez, Emilia Alors-Pérez, et al.
Cancers|July 29, 2023
Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and NeckAnagha Gogate, Bryan Bennett, Zia Poonja, et al.
Frontiers in Medicine|December 6, 2021
Deciphering CHFR Role in Pancreatic Ductal AdenocarcinomaIranzu González-Borja, Emilia Alors-Pérez, Irene Amat, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 17, 2023
Indicators to evaluate quality of care in head and neck cancer in SpainJuan Jesús Cruz Hernández, Virginia Arrazubi Arrula, Yolanda Escobar Álvarez, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2026
Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC studyLara Iglesias Docampo, Neus Basté, Marc Oliva, et al.
Pageof 4